PriceTargets.com logo

Cencora - COR Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $259.44
  • Forecasted Upside: 13.04%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$229.51 As of 10/30/2024 03:52 PM ET
▼ -2.26 (-0.98%)

This chart shows the closing price for COR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cencora Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for COR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for COR

Analyst Price Target is $259.44
▲ +13.04% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Cencora in the last 3 months. The average price target is $259.44, with a high forecast of $287.00 and a low forecast of $224.00. The average price target represents a 13.04% upside from the last price of $229.51.

This chart shows the closing price for COR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 10 polled investment analysts is to moderate buy stock in Cencora. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2024

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/8/2024Evercore ISILower TargetOutperform ➝ Outperform$270.00 ➝ $250.00
10/7/2024Leerink PartnersLower TargetOutperform ➝ Outperform$277.00 ➝ $275.00
9/18/2024Bank of AmericaReiterated RatingBuy ➝ Neutral$275.00 ➝ $245.00
9/6/2024Robert W. BairdLower TargetOutperform ➝ Outperform$287.00 ➝ $283.00
8/21/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$280.00 ➝ $287.00
8/1/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$236.00 ➝ $249.00
8/1/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$285.00 ➝ $287.00
7/9/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$280.00 ➝ $285.00
6/27/2024Leerink PartnersReiterated RatingOutperform ➝ Outperform$275.00 ➝ $275.00
5/2/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$275.00 ➝ $277.00
4/30/2024CitigroupBoost TargetBuy ➝ Buy$265.00 ➝ $280.00
2/26/2024Leerink PartnrsReiterated RatingOutperform
2/26/2024Leerink PartnersInitiated CoverageOutperform$261.00
2/5/2024MizuhoBoost TargetNeutral ➝ Neutral$192.00 ➝ $224.00
1/3/2024BarclaysInitiated CoverageOverweight$242.00
12/14/2023Wells Fargo & CompanyInitiated CoverageEqual Weight$213.00
10/11/2023Evercore ISIBoost Target$210.00 ➝ $225.00
8/7/2023TD CowenBoost TargetOutperform ➝ Outperform$205.00 ➝ $215.00
8/3/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$176.00 ➝ $190.00
7/17/2023Bank of AmericaBoost Target$200.00 ➝ $212.00
7/11/2023MizuhoBoost Target$174.00 ➝ $192.00
6/7/2023Bank of AmericaBoost TargetBuy$195.00 ➝ $200.00
5/26/2023888Reiterated RatingMaintains
5/3/2023Deutsche Bank AktiengesellschaftBoost Target$174.00 ➝ $182.00
5/3/2023MizuhoBoost Target$170.00 ➝ $174.00
5/3/2023BarclaysBoost TargetOverweight$182.00 ➝ $189.00
3/31/2023CitigroupInitiated CoverageBuy$185.00
2/2/2023Robert W. BairdBoost TargetOutperform$199.00 ➝ $201.00
2/2/2023MizuhoBoost TargetNeutral$162.00 ➝ $170.00
1/31/2023UBS GroupBoost TargetBuy$184.00 ➝ $190.00
1/31/2023Evercore ISIReiterated RatingOutperform$185.00
1/12/2023ArgusBoost TargetBuy$170.00 ➝ $190.00
1/11/2023Robert W. BairdBoost TargetOutperform$195.00 ➝ $199.00
11/22/2022Credit Suisse GroupBoost TargetOutperform$175.00 ➝ $182.00
11/4/2022Robert W. BairdBoost Target$188.00 ➝ $195.00
10/18/2022CowenLower TargetOutperform$170.00 ➝ $169.00
10/18/2022CowenLower TargetOutperform$170.00 ➝ $169.00
10/11/2022Bank Of America (Bofa)UpgradeBuy
10/11/2022Bank of AmericaUpgradeNeutral ➝ Buy$160.00 ➝ $169.00
8/22/2022Morgan StanleyBoost TargetEqual Weight$175.00 ➝ $176.00
8/4/2022Credit Suisse GroupLower TargetOutperform$180.00 ➝ $175.00
7/20/2022ArgusBoost TargetBuy$160.00 ➝ $170.00
6/13/2022UBS GroupBoost TargetBuy$144.00 ➝ $174.00
6/9/2022CowenLower TargetOutperform$171.00 ➝ $170.00
6/9/2022CowenLower Target$171.00 ➝ $170.00
6/7/2022Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$167.00 ➝ $178.00
6/3/2022Evercore ISILower Target$165.00
5/27/2022Morgan StanleyLower TargetEqual Weight$178.00 ➝ $175.00
5/26/2022BarclaysUpgradeEqual Weight ➝ Overweight$175.00 ➝ $182.00
5/25/2022Deutsche Bank AktiengesellschaftLower Target$168.00 ➝ $167.00
5/5/2022Robert W. BairdBoost Target$179.00 ➝ $187.00
5/5/2022Deutsche Bank AktiengesellschaftBoost Target$153.00 ➝ $168.00
5/5/2022MizuhoBoost Target$139.00 ➝ $162.00
4/12/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$142.00 ➝ $178.00
3/14/2022ArgusBoost Target$140.00 ➝ $160.00
2/3/2022Robert W. BairdBoost Target$175.00 ➝ $179.00
2/3/2022MizuhoBoost TargetNeutral$130.00 ➝ $139.00
1/11/2022BarclaysBoost TargetEqual Weight$135.00 ➝ $152.00
1/6/2022ScotiabankDowngradeOutperform ➝ Sector Perform
12/17/2021Morgan StanleyBoost TargetOverweight$141.00 ➝ $142.00
11/12/2021Deutsche Bank AktiengesellschaftBoost TargetHold$136.00 ➝ $153.00
11/8/2021Credit Suisse GroupBoost TargetOutperform$144.00 ➝ $145.00
11/5/2021BarclaysBoost TargetEqual Weight$130.00 ➝ $135.00
8/31/2021Morgan StanleyBoost TargetOverweight$138.00 ➝ $141.00
8/5/2021Credit Suisse GroupBoost TargetOutperform$132.00 ➝ $144.00
8/5/2021Robert W. BairdBoost TargetOutperform$156.00 ➝ $162.00
6/20/2021Robert W. BairdReiterated RatingBuy
5/6/2021BarclaysBoost TargetEqual Weight$122.00 ➝ $130.00
2/9/2021MizuhoBoost TargetNeutral$104.00 ➝ $114.00
2/8/2021Morgan StanleyBoost TargetOverweight$130.00 ➝ $138.00
2/8/2021CowenBoost TargetOutperform$145.00 ➝ $150.00
2/5/2021Credit Suisse GroupBoost TargetOutperform$123.00 ➝ $127.00
2/4/2021Evercore ISIUpgradeIn-Line ➝ Outperform
2/1/2021CowenBoost TargetOutperform$129.00 ➝ $145.00
1/21/2021ArgusBoost TargetBuy$120.00 ➝ $140.00
1/7/2021Deutsche Bank AktiengesellschaftBoost TargetHold$111.00 ➝ $115.00
1/6/2021Bank of AmericaUpgradeUnderperform ➝ Neutral
11/13/2020MizuhoBoost TargetNeutral$100.00 ➝ $104.00
11/9/2020Credit Suisse GroupBoost TargetOutperform$118.00 ➝ $123.00
11/9/2020Morgan StanleyBoost TargetOverweight$121.00 ➝ $130.00
11/6/2020Deutsche Bank AktiengesellschaftBoost TargetHold$104.00 ➝ $111.00
8/10/2020UBS GroupBoost TargetBuy$99.00 ➝ $112.00
8/10/2020Credit Suisse GroupBoost TargetOutperform$111.00 ➝ $118.00
8/6/2020Morgan StanleyBoost TargetOverweight$112.00 ➝ $121.00
7/21/2020Bank of AmericaBoost TargetUnderperform$85.00 ➝ $88.00
6/15/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$94.00 ➝ $112.00
5/15/2020UBS GroupLower TargetBuy$108.00 ➝ $99.00
5/11/2020Deutsche Bank AktiengesellschaftBoost TargetHold$93.00 ➝ $98.00
5/8/2020Morgan StanleyBoost TargetEqual Weight$84.00 ➝ $94.00
4/22/2020Credit Suisse GroupInitiated CoverageBuy$105.00
4/1/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$93.00 ➝ $106.00
3/27/2020Morgan StanleyLower TargetEqual Weight$98.00 ➝ $84.00
2/7/2020Robert W. BairdUpgradeNeutral ➝ Outperform$112.00
2/2/2020Credit Suisse GroupReiterated RatingBuy$98.00
1/31/2020Robert W. BairdBoost TargetNeutral$93.00 ➝ $94.00
1/31/2020Deutsche Bank AktiengesellschaftBoost TargetHold$79.00 ➝ $93.00
1/19/2020BarclaysReiterated RatingHold$100.00
11/18/2019ArgusReiterated RatingBuy$110.00
(Data available from 10/30/2019 forward)

News Sentiment Rating

1.26 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 21 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2024
  • 8 very positive mentions
  • 22 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
5/3/2024
  • 13 very positive mentions
  • 17 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2024
  • 15 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2024
  • 37 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
8/1/2024
  • 34 very positive mentions
  • 27 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2024
  • 31 very positive mentions
  • 21 positive mentions
  • 5 negative mentions
  • 2 very negative mentions
Mentions as of
9/30/2024
  • 35 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2024

Current Sentiment

  • 35 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Cencora logo
Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
Read More

Today's Range

Now: $229.51
Low: $228.57
High: $231.29

50 Day Range

MA: $231.91
Low: $219.50
High: $243.72

52 Week Range

Now: $229.51
Low: $182.75
High: $247.66

Volume

664,771 shs

Average Volume

1,402,686 shs

Market Capitalization

$45.78 billion

P/E Ratio

24.92

Dividend Yield

0.87%

Beta

0.44

Frequently Asked Questions

What sell-side analysts currently cover shares of Cencora?

The following equities research analysts have issued reports on Cencora in the last year: Bank of America Co., Barclays PLC, Citigroup Inc., Evercore ISI, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Mizuho, Robert W. Baird, StockNews.com, and Wells Fargo & Company.
View the latest analyst ratings for COR.

What is the current price target for Cencora?

9 Wall Street analysts have set twelve-month price targets for Cencora in the last year. Their average twelve-month price target is $259.44, suggesting a possible upside of 13.0%. JPMorgan Chase & Co. has the highest price target set, predicting COR will reach $287.00 in the next twelve months. Mizuho has the lowest price target set, forecasting a price of $224.00 for Cencora in the next year.
View the latest price targets for COR.

What is the current consensus analyst rating for Cencora?

Cencora currently has 3 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for COR.

What other companies compete with Cencora?

Other companies that are similar to Cencora include McKesson, Cardinal Health, Henry Schein, Patterson Companies and Owens & Minor. Learn More about companies similar to Cencora.

How do I contact Cencora's investor relations team?

Cencora's physical mailing address is 1300 MORRIS DRIVE, CHESTERBROOK PA, 19087. The company's listed phone number is (610) 727-7000 and its investor relations email address is [email protected]. The official website for Cencora is www.amerisourcebergen.com. Learn More about contacing Cencora investor relations.